Comparative Pharmacology
Head-to-head clinical analysis: LUMOXITI versus LYMPHIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMOXITI versus LYMPHIR.
LUMOXITI vs LYMPHIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CD3-CD19 bispecific monoclonal antibody that binds CD3 on T cells and CD19 on B cells, leading to T-cell activation and cytokine release, resulting in B-cell lysis.
Denileukin diftitox is a recombinant fusion protein composed of diphtheria toxin fragments A and B and interleukin-2 (IL-2). It targets cells expressing the IL-2 receptor, leading to internalization and inhibition of protein synthesis, resulting in cell death.
Intravenous injection of 0.03 mg/kg over 30 minutes on days 1, 3, and 5 of each 28-day cycle until disease progression or unacceptable toxicity.
For cutaneous T-cell lymphoma: 18 mcg/kg administered intravenously over 30 minutes on days 1-3 and days 8-10 of a 28-day cycle.
None Documented
None Documented
8-15 hours (mean 11 hours) in patients with normal renal function; prolonged in renal impairment
Terminal elimination half-life approximately 11 days (range 8–15 days) in patients with relapsed/refractory peripheral T-cell lymphoma.
Renal (90% as unchanged drug via glomerular filtration and active tubular secretion), biliary/fecal (<5%)
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion of intact drug (<1%).
Category C
Category C
Immunotoxin
Immunotoxin